Pembina Pipeline (PBA) Reaches $31.42 Formed H&S; SELLAS LIFE SCIENCES GROUP (GALE) Had 3 Bullish Analysts

SELLAS LIFE SCIENCES GROUP INC (NASDAQ:GALE) Logo

Pembina Pipeline Corporation (PBA) formed H&S with $29.22 target or 7.00% below today’s $31.42 share price. Pembina Pipeline Corporation (PBA) has $15.92B valuation. The stock decreased 0.13% or $0.04 during the last trading session, reaching $31.42. About 511,100 shares traded. Pembina Pipeline Corporation (NYSE:PBA) has declined 3.38% since April 26, 2017 and is downtrending. It has underperformed by 14.93% the S&P500.

Among 7 analysts covering Galena Biopharma (NASDAQ:GALE), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Galena Biopharma had 17 analyst reports since August 7, 2015 according to SRatingsIntel. On Friday, March 11 the stock rating was maintained by Roth Capital with “Buy”. The firm has “Buy” rating given on Tuesday, November 10 by TH Capital. The stock of SELLAS LIFE SCIENCES GROUP INC (NASDAQ:GALE) has “Market Perform” rating given on Wednesday, June 29 by Raymond James. Cantor Fitzgerald maintained the shares of GALE in report on Friday, August 7 with “Sell” rating. The firm has “Mkt Perform” rating by FBR Capital given on Monday, February 6. Maxim Group maintained it with “Buy” rating and $4 target in Tuesday, December 22 report. On Wednesday, August 9 the stock rating was maintained by Maxim Group with “Hold”. The firm earned “Buy” rating on Friday, August 7 by MLV. The stock has “Hold” rating by Maxim Group on Thursday, February 2. The stock of SELLAS LIFE SCIENCES GROUP INC (NASDAQ:GALE) has “Buy” rating given on Friday, December 2 by Maxim Group. See SELLAS LIFE SCIENCES GROUP INC (NASDAQ:GALE) latest ratings:

18/12/2017 Broker: Raymond James Rating: Hold

Analysts await Pembina Pipeline Corporation (NYSE:PBA) to report earnings on May, 3 after the close. They expect $0.49 earnings per share, up 32.43% or $0.12 from last year’s $0.37 per share. PBA’s profit will be $248.27M for 16.03 P/E if the $0.49 EPS becomes a reality. After $0.52 actual earnings per share reported by Pembina Pipeline Corporation for the previous quarter, Wall Street now forecasts -5.77% negative EPS growth.

Among 5 analysts covering Pembina Pipeline (NYSE:PBA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Pembina Pipeline has $45.0 highest and $43 lowest target. $43’s average target is 36.86% above currents $31.42 stock price. Pembina Pipeline had 8 analyst reports since August 10, 2015 according to SRatingsIntel. The firm earned “Overweight” rating on Thursday, October 13 by JP Morgan. On Monday, November 7 the stock rating was upgraded by GMP Securities to “Buy”. The firm has “Outperform” rating by Credit Suisse given on Friday, December 11. The firm earned “Outperform” rating on Monday, August 10 by RBC Capital Markets. ational Bank Financial downgraded the shares of PBA in report on Monday, July 18 to “Sector Perform” rating. As per Monday, June 20, the company rating was downgraded by Credit Suisse. RBC Capital Markets maintained Pembina Pipeline Corporation (NYSE:PBA) rating on Monday, November 9. RBC Capital Markets has “Outperform” rating and $43 target.

Galena Biopharma, Inc., a biopharmaceutical company, develops hematology and oncology therapeutics that address unmet medical needs. The company has market cap of $. The firm develops GALE-401 , which completed Phase II clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. It currently has negative earnings. It also develops NeuVax (nelipepimut-S), which is in Phase IIb clinical trial in combination with trastuzumab for HER2 1+ and 2+ node positive and high-risk node negative breast cancer patients; Phase II clinical trial in combination with trastuzumab for HER2 3+ breast cancer patients; Phase II clinical trial for women with ductal carcinoma in situ of the breast; and Phase II clinical trial for patients with gastric cancer.